The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A review of Formulations of Commercially Available Antibodies
Abstract
This review identified 126 commercially available antibodies approved globally between 1986 and February 2021 including 10 antibody drug conjugates, 16 biosimilars, and 3 antibody fragments. Prior to 2014 there were ≤ 5 approved each year, but after 2014 there have been ≥ 7 approved each year with the years 2017 and 2020 having the most at 17 each. A total of 136 products were identified of which 36 are lyophilized powders and 100 are solutions. The routes of administration are mainly subcutaneous or intravenous infusion with three intravenous bolus, two intravitreal, and one intramuscular. The subcutaneous products are ready-to-use solutions or reconstituted lyophilized powders that do not require dilution while most intravenous products are concentrates that require dilution into saline or another intravenous fluid prior to infusion. Most are packaged in single-dose units and the exception of multi-use is Herceptin® and its biosimilars. The package configurations are vials, prefilled autoinjectors, or prefilled syringes. A typical antibody formulation contains an antibody, an excipient to adjust tonicity or osmolality for solutions or a lyoprotectant for lyophilized powders, a buffer, and a surfactant. The ionic tonicity-adjusting excipient is mainly sodium chloride and the non-ionic osmolality-adjusting excipients include sucrose, trehalose, mannitol, maltose, and sorbitol. The lyoprotectants are trehalose and sucrose. The pH range is 4.8-8.0 and the buffers or pH-modifying agents include histidine, citrate, succinate, acetate, phosphate, glutamate, adipic acid, aspartic acid, lactic acid, tromethamine, and 2-(N-morpholino)-ethanesulfonic acid. The surfactants include mostly polysorbate 20 or polysorbate 80, with four containing poloxamer 188, and one that does not contain a surfactant but contains PEG 3350. One product does not contain a buffer, and 12 do not contain a surfactant. The viscosity-lowering excipients are sodium chloride and the amino acids arginine, glycine, proline, and lysine. Arginine may also function to adjust ionic strength and minimize aggregation. Human serum albumin is used in 2 products for intravenous infusion. Other excipients include methionine as an anti-oxidant, and EDTA or DTPA as chelating agents. The maximum volume of subcutaneous injection is 15 mL administered over 3-5 minutes, but the typically volume is 0.5-2 mL. Five fixed-dose combinations have recently been approved and four contain hyaluronidase to assist the large volume subcutaneous injection of up to 15 mL, while one is a fixed-dose combination for intravenous with three antibodies. Prefilled autoinjectors and syringes are becoming more common and many come affixed with a needle of 27-gauge or 29-gauge, while a few have a 26-gauge or a 30-gauge needle. Recent advancements include hyaluronidase to assist the large subcutaneous injection volume of 5-15 mL, fixed-dose combinations, buffer-free formulation, and smaller subcutaneous injection volume (0.1 mL).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slade, L., Levine, H., & Reid, D. S. (1991) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408399109527543 · Cited by 1,485
Challenges in the development of high protein concentration formulations
Shire, S. J., Shahrokh, Z., & Liu, J. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20079 · Cited by 882
Kerwin, B. A. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21190 · Cited by 792
An infrared spectroscopic study of the interactions of carbohydrates with dried proteins
Carpenter, J. F., & Crowe, J. H. (1989) · Biochemistry · doi:10.1021/bi00435a044 · Cited by 758
Challenges in the Development of High Protein Concentration Formulations
Shire, S. J., Shahrokh, Z., & Liu, J. (2010) · Current Trends in Monoclonal Antibody Development and Manufacturing · doi:10.1007/978-0-387-76643-0_9 · Cited by 657
Mensink, M. A., Frijlink, H. W., van der Voort Maarschalk, K., & Hinrichs, W. L. J. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.01.024 · Cited by 492
Crowe, J. H., Carpenter, J. F., Crowe, L. M., & Anchordoguy, T. J. (1990) · Cryobiology · doi:10.1016/0011-2240(90)90023-w · Cited by 467
Chang, L. (., Shepherd, D., Sun, J., Ouellette, D., Grant, K. L., Tang, X. (., & Pikal, M. J. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20364 · Cited by 461
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447
Liu, J., Nguyen, M. D. H., Andya, J. D., & Shire, S. J. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20347 · Cited by 436
Cited by
Designing antibodies as therapeutics
Carter, P. J., & Rajpal, A. (2022) · Cell · doi:10.1016/j.cell.2022.05.029 · Cited by 267
Vidal-Henriquez, E., Holder, T., Lee, N. F., Pompe, C., & Teese, M. G. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.10.026 · Cited by 9
Metadata
- Authors
- Strickley, R. G., & Lambert, W. J.
- Venue
- Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 110
- Issue
- 7
- Pages
- 2590-2608.e56
- ISSN
- 0022-3549 (ISSN-L)
- OpenAlex
- W3142072058
- Cited by
- 271
- References
- 30
- FWCI
- 18.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A review of Formulations of Commercially Available Antibodies. https://app.cochat.ai/papers/10.1016/j.xphs.2021.03.017
- The paper
- Strickley, R. G., & Lambert, W. J. (2021). A review of Formulations of Commercially Available Antibodies. Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.xphs.2021.03.017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.